ID: ALA2370898

Max Phase: Preclinical

Molecular Formula: C42H73N13O10

Molecular Weight: 920.13

Molecule Type: Protein

Associated Items:

Representations

Canonical SMILES:  CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CCO)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)C(C)(C)N)C(C)C)[C@@H](C)CC)C(=O)O

Standard InChI:  InChI=1S/C42H73N13O10/c1-9-23(5)31(37(61)50-28(19-25-20-46-21-48-25)38(62)55-17-12-14-29(55)35(59)54-32(39(63)64)24(6)10-2)53-34(58)27(15-18-56)49-36(60)30(22(3)4)52-33(57)26(13-11-16-47-41(43)44)51-40(65)42(7,8)45/h20-24,26-32,56H,9-19,45H2,1-8H3,(H,46,48)(H,49,60)(H,50,61)(H,51,65)(H,52,57)(H,53,58)(H,54,59)(H,63,64)(H4,43,44,47)/t23-,24-,26-,27-,28-,29-,30-,31-,32-/m0/s1

Standard InChI Key:  CRIANIIYLXLGBY-SVDJVBGPSA-N

Associated Targets(non-human)

Angiotensin II receptor 1735 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Angiotensin II receptor (AT-1) type-1 1480 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: ProteinTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 920.13Molecular Weight (Monoisotopic): 919.5603AlogP: -2.14#Rotatable Bonds: 27
Polar Surface Area: 371.54Molecular Species: ZWITTERIONHBA: 12HBD: 12
#RO5 Violations: 3HBA (Lipinski): 23HBD (Lipinski): 15#RO5 Violations (Lipinski): 3
CX Acidic pKa: 3.88CX Basic pKa: 10.78CX LogP: -4.18CX LogD: -5.12
Aromatic Rings: 1Heavy Atoms: 65QED Weighted: 0.03Np Likeness Score: 0.13

References

1. Matsoukas JM, Agelis G, Wahhab A, Hondrelis J, Panagiotopoulos D, Yamdagni R, Wu Q, Mavromoustakos T, Maia HL, Ganter R..  (1995)  Differences in backbone structure between angiotensin II agonists and type I antagonists.,  38  (23): [PMID:7473593] [10.1021/jm00023a005]

Source